These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31100004)

  • 21. "Minimalist" Nanovaccine Constituted from Near Whole Antigen for Cancer Immunotherapy.
    Wang K; Wen S; He L; Li A; Li Y; Dong H; Li W; Ren T; Shi D; Li Y
    ACS Nano; 2018 Jul; 12(7):6398-6409. PubMed ID: 29927574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes.
    Perricone MA; Smith KA; Claussen KA; Plog MS; Hempel DM; Roberts BL; St George JA; Kaplan JM
    J Immunother; 2004; 27(4):273-81. PubMed ID: 15235388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression.
    Ragonnaud E; Andersson AM; Pedersen AE; Laursen H; Holst PJ
    Vaccine; 2016 Apr; 34(18):2147-56. PubMed ID: 27004934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
    Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
    Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines.
    Nair SK; Boczkowski D; Snyder D; Gilboa E
    Eur J Immunol; 1997 Mar; 27(3):589-97. PubMed ID: 9079797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma.
    Mitchell MS; Kan-Mitchell J; Morrow PR; Darrah D; Jones VE; Mescher MF
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):76-83. PubMed ID: 14734454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy.
    Zhang S; Feng Y; Meng M; Li Z; Li H; Lin L; Xu C; Chen J; Hao K; Tang Z; Tian H; Chen X
    Biomaterials; 2022 Oct; 289():121794. PubMed ID: 36113330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
    Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
    J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
    Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
    J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model.
    Gupta S; Termini JM; Rivas Y; Otero M; Raffa FN; Bhat V; Farooq A; Stone GW
    Vaccine; 2015 Sep; 33(38):4798-806. PubMed ID: 26241951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model.
    Zhang H; Liu C; Zhang F; Geng F; Xia Q; Lu Z; Xu P; Xie Y; Wu H; Yu B; Wu J; Yu X; Kong W
    Vaccine; 2016 May; 34(24):2648-55. PubMed ID: 27113167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanoparticles built by self-assembly of amphiphilic gamma-PGA can deliver antigens to antigen-presenting cells with high efficiency: a new tumor-vaccine carrier for eliciting effector T cells.
    Yoshikawa T; Okada N; Oda A; Matsuo K; Matsuo K; Kayamuro H; Ishii Y; Yoshinaga T; Akagi T; Akashi M; Nakagawa S
    Vaccine; 2008 Mar; 26(10):1303-13. PubMed ID: 18255205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade.
    Mougel A; Terme M; Tanchot C
    Front Immunol; 2019; 10():467. PubMed ID: 30923527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden.
    Prins RM; Bruhn KW; Craft N; Lin JW; Kim CH; Odesa SK; Miller JF; Liau LM
    Neurosurgery; 2006 Jan; 58(1):169-78; discussion 169-78. PubMed ID: 16385341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigen-containing liposomes engrafted with flagellin-related peptides are effective vaccines that can induce potent antitumor immunity and immunotherapeutic effect.
    Faham A; Altin JG
    J Immunol; 2010 Aug; 185(3):1744-54. PubMed ID: 20610649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myeloid-derived Suppressor Cells Elimination by 5-Fluorouracil Increased Dendritic Cell-based Vaccine Function and Improved Immunity in Tumor Mice.
    Khosravianfar N; Hadjati J; Namdar A; Boghozian R; Hafezi M; Ashourpour M; Kheshtchin N; Banitalebi M; Mirzaei R; Razavi SA
    Iran J Allergy Asthma Immunol; 2018 Feb; 17(1):47-55. PubMed ID: 29512369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ratio of IgG:IgM antibodies to sialyl Lewis(x) and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice.
    Ravindranath MH; Kelley MC; Jones RC; Amiri AA; Bauer PM; Morton DL
    Int J Cancer; 1998 Jan; 75(1):117-24. PubMed ID: 9426699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice.
    DeMatos P; Abdel-Wahab Z; Vervaert C; Hester D; Seigler H
    J Surg Oncol; 1998 Jun; 68(2):79-91. PubMed ID: 9624036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanovaccine Incorporated with Hydroxychloroquine Enhances Antigen Cross-Presentation and Promotes Antitumor Immune Responses.
    Liu J; Liu X; Han Y; Zhang J; Liu D; Ma G; Li C; Liu L; Kong D
    ACS Appl Mater Interfaces; 2018 Sep; 10(37):30983-30993. PubMed ID: 30136844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.